findmyKOL

Natalie Torok, MD

Enriched profile

Professor of Medicine (Gastroenterology and Hepatology), Stanford University School of Medicine · Stanford University School of Medicine

ORCIDNPI
Region🇺🇸 Stanford, CA · West · United StatesSpecialtyGastroenterologyFocusLiver Disease Diagnosis and Treatment+4
Active KOLfindmyKOL typefindmyKOL type: our influence ranking, shown when you reveal the full profileLatest publication2025Online presenceNone verifiedPayments2024–2024NIH funding2005–2026

Natalie Torok is Professor of Medicine (Gastroenterology and Hepatology), Stanford University School of Medicine at Stanford University School of Medicine. OpenAlex indexes 127 publications with 5,230 citations (h-index 38); ClinicalTrials.gov lists 3 registered studies with this person as an investigator.

Data verified 17 Aug 2026

Overview

Updated 27 Aug 2026

Natalie Torok, M.D., is Professor of Medicine (Gastroenterology and Hepatology), Stanford University School of Medicine. The public record shows 127 publications with 5,230 citations (h-index 38), centered on Liver Disease Diagnosis and Treatment, Liver physiology and pathology, MicroRNA in disease regulation. It also documents an investigator role on 3 registered clinical trials, industry payments reported by 2 companies, 11 NIH-funded awards (2005–2026).

  • Most recent indexed publication: 2025 · Nature
  • Top research focus: Liver Disease Diagnosis and Treatment
  • 3 registered trials on ClinicalTrials.gov
  • Open Payments reporting from 2 companies

Generated from the cited public record · current as of 27 Aug 2026. Every fact links its source below.

Indications focus

from trials led + research topics
NASH / NAFLD / MASH3 trialsFatty Liver3 trialsFatty Liver, Alcoholic3 trialsNon-alcoholic Fatty Liver Disease2 trialsMetabolic Syndrome1 trial

Research focus

OpenAlex concept fingerprint
Liver Disease Diagnosis and TreatmentLiver physiology and pathologyMicroRNA in disease regulationLiver Diseases and ImmunityCancer-related molecular mechanisms research

Drugs & molecules

across trials, industry payments and publications
ResmetiromClinical trialsIndustry payments1Publications

Works with

trial sponsors and companies reporting payments
GlaxoSmithKline, LLC.Clinical trialsIndustry payments17Madrigal PharmaceuticalsClinical trialsIndustry payments1Natalie TorokClinical trials1Industry payments

Scholarship

indexed output and impact (OpenAlex)
View publications ↓
127publications

Distinct works indexed by OpenAlex, matched via ORCID; 5 in PubMed.

5,230citations

Total citations across indexed works.

38h-index

Hirsch index (OpenAlex). i10-index 58.

Clinical & industry

trials, payments and federal funding
3clinical trials

Investigator role on registered studies.

View trials
2companies · 2024–2024

Companies reporting payments to CMS. Facts, not judgments.

View payments
11NIH grants · 2005–2026

Federally funded research awards.

View funding

Contact

The practice address and phone this provider lists in the federal NPPES (CMS) registry.

Practice address

Telephone

Practice address and telephone from the federal NPPES registry.

Sign in to view contact details →

Clinical trials

Updated 27 Aug 2026

Listed as an investigator on 3 registered studies on ClinicalTrials.gov. The most recent:

Industry payments

Updated 27 Aug 2026

2 companies reported payments to CMS in program years 2024–2024. These are public disclosures, not judgments. The latest:

Medicare prescribing footprint (2024)

The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.

  • Cancer & immunology

    34.1%
    Calcineurin inhibitor34.1%
    Tacrolimus78%Envarsus Xr22%
    Part D<11 patients
  • Metabolism & gastrointestinal

    21.6%
    Potassium supplement7.4%
    Potassium Chloride100%
    Part D<11 patients
    Bile Acid7.4%
    Ursodiol100%
    Part D<11 patients
  • Anti-infectives

    19.3%
    Nucleoside and nucleotide reverse transcriptase inhibitors19.3%
    Tenofovir Disoproxil Fumarate62%Vemlidy38%
    Part D<11 patients
2 more therapeutic areas behind the reveal.Reveal →
Where care is delivered (Part B)0% facility · 100% office

Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.

NIH funding

Updated 27 Aug 2026

11 NIH research awards on record, funded 20052026 per NIH RePORTER. The latest:

48 more award records behind the reveal.Reveal →

Publications

Updated 27 Aug 2026

Their five most recent publications, matched to their ORCID record and linked to PubMed.

Network

Updated 27 Aug 2026

The people this person publishes with most, by number of co-authored papers. Names link to their own profile when we have one.

Background & recognition

Updated 27 Aug 2026

Credentials, appointments and honors, newest first, each linked to the public source it came from.

Education

degrees and training on record
  • Board Certified

    Gastroenterology, American Board of Internal Medicine

    2025
    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →med.stanford.edu
  • Gastroenterology Fellowship

    Mayo Clinic, Rochester, MN

    2003
    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →med.stanford.edu
  • Internal Medicine Residency

    Mayo Clinic, Rochester, MN

    1999
    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →med.stanford.edu
  • MD

    Semmelweis University Medical School, Hungary

    1988
    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →med.stanford.edu

Editorial & leadership roles

journal and society appointments
  • Associate Editor

    Hepatology

    2021
    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →med.stanford.edu
  • Associate Editor

    Hepatology Communications

    2021
    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →med.stanford.edu
  • Associate Editor

    American Journal of Physiology Gastrointestinal and Liver Physiology

    2018
    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →med.stanford.edu
5 more roles behind the reveal.Reveal →

Awards & honors

honors on the public record

Secondary affiliations

appointments beyond the home institution
2 more affiliations behind the reveal.Reveal →

Every item links to where we found it. verified means we've confirmed it in more than one place; provisional means we found it and are still confirming.

Similar KOLs

Other experts from the same institution or the same specialty.